Business Description
ChemoMetec AS
ISIN : DK0060055861
Compare
Compare
Traded in other countries / regions
CHEMM.Denmark0DZ0.UKCHY.Germany IPO Date
2007-10-27Description
ChemoMetec AS specializes in designing, developing, and producing instruments using patented technology in cell counting and evaluation. It is engaged in the manufacturing and marketing of analytical instruments used for quantitative analysis of cells in liquids. Its applications includeĀ Cell Analysis and counting of Mammalian Cells, Yeast Cells, and Sperm Cells. It provides platforms for the determination of viability and cell count of yeast, veterinary semen, mammalian cells, and somatic cells as well asĀ image analysis. It has four segments instruments; consumables; services and others, and the majority of its revenue is generated from the Consumable segment.
Financial Strength
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 71.28 | |||||
| Equity-to-Asset | 0.84 | |||||
| Debt-to-Equity | 0.01 | |||||
| Debt-to-EBITDA | 0.02 | |||||
| Interest Coverage | 938.69 | |||||
| Piotroski F-Score | 5/9 | |||||
| Altman Z-Score | 50.78 | |||||
| Beneish M-Score | -2.1 | |||||
| WACC vs ROIC | ||||||
Growth Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 13.2 | |||||
| 3-Year EBITDA Growth Rate | 13.3 | |||||
| 3-Year EPS without NRI Growth Rate | 15.2 | |||||
| 3-Year FCF Growth Rate | 0.9 | |||||
| 3-Year Book Growth Rate | 28.7 | |||||
| Future 3-5Y EPS without NRI Growth Rate | 20.26 | |||||
| Future 3-5Y Total Revenue Growth Rate | 14.81 |
Momentum Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 67.62 | |||||
| 9-Day RSI | 60.46 | |||||
| 14-Day RSI | 58.82 | |||||
| 6-1 Month Momentum % | 56.88 | |||||
| 12-1 Month Momentum % | 22.38 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 4.97 | |||||
| Quick Ratio | 3.76 | |||||
| Cash Ratio | 3.01 | |||||
| Days Inventory | 1057.04 | |||||
| Days Sales Outstanding | 52.78 | |||||
| Days Payable | 121.64 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Yield % | 0.82 | |||||
| Dividend Payout Ratio | 0.77 | |||||
| 3-Year Dividend Growth Rate | 58.7 | |||||
| Forward Dividend Yield % | 0.82 | |||||
| 5-Year Yield-on-Cost % | 0.82 | |||||
| Shareholder Yield % | 0.82 |
Profitability Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 90.13 | |||||
| Operating Margin % | 41.43 | |||||
| Net Margin % | 33.41 | |||||
| FCF Margin % | 20.96 | |||||
| ROE % | 25.6 | |||||
| ROA % | 21.2 | |||||
| ROIC % | 41.16 | |||||
| ROC (Joel Greenblatt) % | 105.78 | |||||
| ROCE % | 32.72 | |||||
| Years of Profitability over Past 10-Year | 10 |
GF Value Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 64.88 | |||||
| Forward PE Ratio | 48.15 | |||||
| PE Ratio without NRI | 64.88 | |||||
| Shiller PE Ratio | 115.43 | |||||
| PEG Ratio | 2.42 | |||||
| PS Ratio | 21.67 | |||||
| PB Ratio | 15.64 | |||||
| Price-to-Tangible-Book | 18.44 | |||||
| Price-to-Free-Cash-Flow | 103.38 | |||||
| Price-to-Operating-Cash-Flow | 68.5 | |||||
| EV-to-EBIT | 46.21 | |||||
| EV-to-EBITDA | 42.11 | |||||
| EV-to-Revenue | 20.03 | |||||
| EV-to-FCF | 100.02 | |||||
| Price-to-Projected-FCF | 5.83 | |||||
| Price-to-DCF (Earnings Based) | 1.65 | |||||
| Price-to-DCF (FCF Based) | 2.62 | |||||
| Price-to-Median-PS-Value | 1.51 | |||||
| Price-to-Peter-Lynch-Fair-Value | 2.55 | |||||
| Price-to-Graham-Number | 7.22 | |||||
| Price-to-Net-Current-Asset-Value | 22.93 | |||||
| Price-to-Net-Cash | 46.98 | |||||
| Earnings Yield (Greenblatt) % | 2.17 | |||||
| FCF Yield % | 1.01 | |||||
| Forward Rate of Return (Yacktman) % | 20.91 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Ā
Total Annual Return % Ā
ChemoMetec AS Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil kr) | 407.87 | ||
| EPS (TTM) (kr) | 7.83 | ||
| Beta | 1.2 | ||
| Volatility % | 63.17 | ||
| 14-Day RSI | 58.82 | ||
| 14-Day ATR (kr) | 14.09438 | ||
| 20-Day SMA (kr) | 490.93 | ||
| 12-1 Month Momentum % | 22.38 | ||
| 52-Week Range (kr) | 282 - 553.5 | ||
| Shares Outstanding (Mil) | 17.4 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
ChemoMetec AS Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
ChemoMetec AS Stock Events
| Event | Date | Price(kr) | ||
|---|---|---|---|---|
| No Event Data | ||||
ChemoMetec AS Frequently Asked Questions
What is ChemoMetec AS(LTS:0DZ0)'s stock price today?
The current price of LTS:0DZ0 is kr490.05. The 52 week high of LTS:0DZ0 is kr553.50 and 52 week low is kr282.00.
When is next earnings date of ChemoMetec AS(LTS:0DZ0)?
The next earnings date of ChemoMetec AS(LTS:0DZ0) is 2025-02-05.
Does ChemoMetec AS(LTS:0DZ0) pay dividends? If so, how much?
TheĀ Dividend Yield % Ā of ChemoMetec AS(LTS:0DZ0) is 0.82% (As of Today), HighestĀ Dividend Payout RatioĀ of ChemoMetec AS(LTS:0DZ0) was 2.15. The lowest was 0.29. And the median was 0.77. The Ā Forward Dividend Yield % of ChemoMetec AS(LTS:0DZ0) is 0.82%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers